P148 | Effects of new anti-diabetic drugs (SGLT2-I and GLP1-RA) in patients suffering from type 2 diabetes mellitus complicated by peripheral artery disease undergoing percutaneous transluminal angioplasty
G. Vurchio, F. Palumbo, N. Argese, C. Tortorella | POC “SS. Annunziata”, Taranto, Italy
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Premises and Purpose of the study: This study explores the impact of SGLT2 inhibitors and GLP-1 receptor agonists on type 2 diabetes mellitus with peripheral artery disease (PAD) patients undergoing percutaneous distal revascularization (PTA). The research aims to assess the short-term effects of these drugs on some clinical parameters and on metabolic balance in this patient population.
Materials and Methods: At ‘SS. Annunziata’ Hospital (Taranto),33 patients with T2DM complicated by PAD undergoing PTA were studied. Divided into SGLT2-i and/or GLP1-RA-treated (11) and other kind of treatment (22), clinical parameters (Leriche-Fontaine stage, recurrence of stenosis and the risk of amputation) were assessed at pre-operative (T0) and 6 months post-surgery(T1). Also, blood-chemical parameters (A1C, lipid profile, renal function, CRP) were examined.
Results: Significant reductions in A1C, CRP, uric acid and triglyceride values were observed regardless of drug treatment. Further categorization, revealed that at T0 the untreated group had a higher CRP value, higher insulin and lower metformin intake, while the treated group had higher triglyceride values. At T1, the treated group showed better renal function, reduced Leriche-Fontaine stage and fewer amputations than the untreated group. The two-way ANOVA showed a positive impact of treatment with the new drugs on renal function.
Conclusions: This study shows SGLT2-i and/or GLP1-1-RA benefits in T2DM patients with PAD: reduced systemic inflammation, improved blood circulation, fewer stenotic recurrences, lower amputation risk.
Altmetrics
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.